Aerie Pharmaceuticals (NASDAQ:AERI) Raised to Sell at BidaskClub

BidaskClub upgraded shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a strong sell rating to a sell rating in a research report released on Tuesday, BidAskClub reports.

Several other equities analysts have also weighed in on the stock. Needham & Company LLC restated a buy rating and issued a $54.00 price objective (down from $74.00) on shares of Aerie Pharmaceuticals in a report on Thursday, August 8th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating and set a $31.00 price objective on the stock in a report on Friday, June 28th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, June 11th. Finally, Mizuho set a $77.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $62.08.

Shares of NASDAQ AERI opened at $23.19 on Tuesday. The company’s 50 day simple moving average is $24.25 and its 200 day simple moving average is $36.91. Aerie Pharmaceuticals has a fifty-two week low of $20.72 and a fifty-two week high of $64.95. The firm has a market capitalization of $1.13 billion, a P/E ratio of -4.99 and a beta of 0.41. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.52 and a quick ratio of 3.27.



Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.80) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.07. Aerie Pharmaceuticals had a negative net margin of 478.81% and a negative return on equity of 89.52%. The business had revenue of $15.84 million for the quarter, compared to analyst estimates of $14.60 million. Sell-side analysts expect that Aerie Pharmaceuticals will post -3.48 EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Management Ii bought 189,555 shares of the stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $24.43 per share, with a total value of $4,630,828.65. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.71% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. JGP Global Gestao de Recursos Ltda. increased its position in shares of Aerie Pharmaceuticals by 10.4% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 8,523 shares of the company’s stock worth $405,000 after acquiring an additional 800 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Aerie Pharmaceuticals by 26.3% during the first quarter. Candriam Luxembourg S.C.A. now owns 604,800 shares of the company’s stock worth $28,729,000 after acquiring an additional 126,000 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Aerie Pharmaceuticals during the first quarter worth $47,000. CWM LLC increased its position in shares of Aerie Pharmaceuticals by 140,037.0% during the first quarter. CWM LLC now owns 37,837 shares of the company’s stock worth $1,797,000 after acquiring an additional 37,810 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Aerie Pharmaceuticals by 49.5% during the fourth quarter. Legal & General Group Plc now owns 17,592 shares of the company’s stock worth $635,000 after acquiring an additional 5,828 shares in the last quarter.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: What is the Federal Reserve?

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.